Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
169.75 EUR | +0.56% | -3.17% | +17.73% |
09-03 | Merck Gets EU Approval for Keytruda Cancer Therapy | DJ |
08-29 | Merck KGaA Doses First Patient in Late-stage Myasthenia Gravis Study | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Revenues | 16.15B | 17.53B | 19.69B | 22.23B | 20.99B | |||||
Total Revenues | 16.15B | 17.53B | 19.69B | 22.23B | 20.99B | |||||
Cost of Goods Sold, Total | 5.95B | 6.78B | 7.32B | 8.5B | 8.56B | |||||
Gross Profit | 10.2B | 10.75B | 12.36B | 13.74B | 12.44B | |||||
Selling General & Admin Expenses, Total | 5.68B | 5.3B | 5.47B | 5.91B | 5.78B | |||||
Stock-Based Compensation (IS) | -14M | 5M | 3M | -7M | 2M | |||||
R&D Expenses | 2.24B | 2.26B | 2.4B | 2.45B | 2.44B | |||||
Other Operating Expenses | -268M | 117M | 133M | 372M | 515M | |||||
Other Operating Expenses, Total | 7.64B | 7.68B | 8.01B | 8.72B | 8.74B | |||||
Operating Income | 2.56B | 3.07B | 4.35B | 5.01B | 3.7B | |||||
Interest Expense, Total | -403M | -328M | -244M | -196M | -260M | |||||
Interest And Investment Income | 66M | 39M | 46M | 71M | 172M | |||||
Net Interest Expenses | -337M | -289M | -198M | -125M | -88M | |||||
Currency Exchange Gains (Loss) | -86M | -60M | -40M | -109M | 51M | |||||
Other Non Operating Income (Expenses) | -1M | 2M | 14M | -3M | 26M | |||||
EBT, Excl. Unusual Items | 2.14B | 2.73B | 4.13B | 4.78B | 3.68B | |||||
Restructuring Charges | -123M | -170M | -82M | -199M | -248M | |||||
Merger & Related Restructuring Charges | -217M | -190M | -119M | -83M | - | |||||
Gain (Loss) On Sale Of Investments | -8M | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | 30M | 92M | 63M | 54M | 132M | |||||
Asset Writedown | -42M | -183M | -54M | -232M | -98M | |||||
Legal Settlements | -42M | 372M | 8M | -6M | -1M | |||||
Other Unusual Items | 0 | -16M | -21M | -23M | 15M | |||||
EBT, Incl. Unusual Items | 1.74B | 2.63B | 3.92B | 4.29B | 3.48B | |||||
Income Tax Expense | 440M | 637M | 859M | 948M | 650M | |||||
Earnings From Continuing Operations | 1.3B | 1.99B | 3.06B | 3.34B | 2.83B | |||||
Earnings Of Discontinued Operations | 28M | - | - | - | - | |||||
Net Income to Company | 1.32B | 1.99B | 3.06B | 3.34B | 2.83B | |||||
Minority Interest | -3M | -7M | -10M | -14M | -10M | |||||
Net Income - (IS) | 1.32B | 1.99B | 3.06B | 3.33B | 2.82B | |||||
Net Income to Common Incl Extra Items | 1.32B | 1.99B | 3.06B | 3.33B | 2.82B | |||||
Net Income to Common Excl. Extra Items | 1.29B | 1.99B | 3.06B | 3.33B | 2.82B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 3.04 | 4.57 | 7.03 | 7.65 | 6.5 | |||||
Basic EPS - Continuing Operations | 2.97 | 4.57 | 7.03 | 7.65 | 6.5 | |||||
Basic Weighted Average Shares Outstanding | 435M | 435M | 435M | 435M | 435M | |||||
Net EPS - Diluted | 3.03 | 4.57 | 7.03 | 7.65 | 6.49 | |||||
Diluted EPS - Continuing Operations | 2.97 | 4.57 | 7.03 | 7.65 | 6.49 | |||||
Diluted Weighted Average Shares Outstanding | 435M | 435M | 435M | 435M | 435M | |||||
Normalized Basic EPS | 3.07 | 3.9 | 5.91 | 6.83 | 5.27 | |||||
Normalized Diluted EPS | 3.07 | 3.9 | 5.91 | 6.83 | 5.27 | |||||
Dividend Per Share | 1.3 | 1.4 | 1.85 | 2.2 | 2.2 | |||||
Payout Ratio | 51.29 | 34.22 | 24.48 | 28.71 | 40.79 | |||||
American Depositary Receipts Ratio (ADR) | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | |||||
Supplemental Items | ||||||||||
EBITDA | 4.24B | 4.59B | 5.83B | 6.56B | 5.23B | |||||
EBITA | 3.68B | 3.93B | 5.16B | 5.84B | 4.48B | |||||
EBIT | 2.56B | 3.07B | 4.35B | 5.01B | 3.7B | |||||
EBITDAR | 4.27B | 4.61B | 5.85B | 6.57B | 5.24B | |||||
Total Revenues (As Reported) | - | - | - | - | - | |||||
Effective Tax Rate - (Ratio) | 25.36 | 24.21 | 21.89 | 22.11 | 18.66 | |||||
Total Current Taxes | 834M | 959M | 1.08B | 1.34B | 1.14B | |||||
Total Deferred Taxes | -453M | -333M | -174M | -369M | -323M | |||||
Normalized Net Income | 1.33B | 1.7B | 2.57B | 2.97B | 2.29B | |||||
Interest Capitalized | 13M | 8M | 11M | 17M | 22M | |||||
Interest on Long-Term Debt | 14M | 15M | 10M | 13M | 14M | |||||
Non-Cash Pension Expense | 58M | 45M | 28M | 44M | 59M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 521M | 413M | 461M | 476M | 515M | |||||
Selling and Marketing Expenses | 4.57B | 4.15B | 4.29B | 4.68B | 4.47B | |||||
General and Administrative Expenses | 1.04B | 1.09B | 1.16B | 1.19B | 1.26B | |||||
Research And Development Expense From Footnotes | 2.27B | 2.29B | 2.41B | 2.52B | 2.44B | |||||
Net Rental Expense, Total | 22M | 18M | 18M | 14M | 11M | |||||
Imputed Operating Lease Interest Expense | 6.63M | 3.82M | 3.2M | 2.25M | 2.44M | |||||
Imputed Operating Lease Depreciation | 15.37M | 14.18M | 14.8M | 11.75M | 8.56M | |||||
Stock-Based Comp., Other (Total) | -6.94M | 22.51M | 3M | -7M | 2M | |||||
Total Stock-Based Compensation | -6.94M | 22.51M | 3M | -7M | 2M |